Randomized Trialhigh evidence
Azetukalner in Adults With Focal Seizures: The X-TOLE2 Phase 3 Randomized Clinical Trial.
JAMA neurology·November 9, 2026·PMID 43002431
Why it mattersDespite many available antiseizure medications, a substantial proportion of patients with focal epilepsy remain drug-resistant. Azetukalner's novel mechanism and robust efficacy in this trial suggest a potential new option for reducing seizure burden in this challenging population.

The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled